Related Experiment Video
Updated: May 21, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention
Leor Perl1, Adi Netzer, Eldad Rechavia
1Rabin Medical Center, The Sackler Faculty of Medicine, Tel Aviv University, 39 Jabotinsky St., Petah-Tikva 49100, Israel. leorperl@gmail.com
Insights
Patients with antiphospholipid antibody syndrome (APS) undergoing percutaneous coronary intervention (PCI) experience higher rates of revascularization and major adverse cardiac events. However, myocardial infarction and mortality rates remain similar compared to other PCI patients.
Area of Science:
- Cardiology
- Immunology
- Vascular Medicine
Background:
- Antiphospholipid antibody syndrome (APS) is associated with increased atherothrombotic risk.
- Limited data exist on the outcomes of APS patients undergoing percutaneous coronary intervention (PCI).
Purpose of the Study:
- To evaluate the long-term clinical outcomes of patients with APS following PCI.
- To compare APS patients undergoing PCI with matched control groups.
Main Methods:
- Retrospective comparison of 19 APS patients who underwent PCI (2003-2008) with 380 matched PCI patients and 1,458 ST-elevation myocardial infarction patients treated with PCI.
- Clinical outcomes assessed over a 6-month to 4-year follow-up period.
Main Results:
- APS patients undergoing PCI had a higher incidence of acute coronary syndrome as the indication for the procedure.
- One-year follow-up revealed significantly higher rates of target vessel revascularization in APS patients.
- This led to increased rates of major adverse cardiac events in the APS group, with no significant differences in MI or mortality.
Conclusions:
- APS patients undergoing PCI demonstrate poorer long-term clinical outcomes primarily due to increased revascularization needs.
- Further research is necessary to elucidate the underlying mechanisms driving these adverse outcomes in APS patients post-PCI.
Objectives:
Patients with antiphospholipid antibody syndrome (APS) have an increased risk of atherothrombotic complications. There are limited data regarding the outcome of patients with APS who undergo percutaneous coronary intervention (PCI). Accordingly, we aimed to assess the long-term outcomes of these patients.
Methods:
Nineteen APS patients who underwent PCI between the years 2003 and 2008 were compared to 380 patients who had undergone PCI during the same period (PCI group) and were matched by age (±5 years), gender, diabetes and hypertension. In addition, APS patients were compared to 1,458 patients with ST segment elevation myocardial infarction (MI) who were treated with PCI during the same period. Six-month to 4-year clinical outcomes were evaluated.
Results:
The indication for PCI in the APS group was acute coronary syndrome in 52.6% of patients. After 1 year of follow-up, patients with APS had higher rates of target vessel revascularization than the other two groups, which translated to higher rates of major adverse cardiac events. There were no differences in MI or mortality rates between the groups.
Conclusions:
Patients with APS who undergo PCI have worse long-term clinical outcomes, driven by higher rates of revascularization, than other patients undergoing PCI. Further study is warranted to examine the mechanisms underlying these findings.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Peripheral Artery Disease I: Introduction
